N/A N=63 Cellular Dynamics of Subcutaneous Fat Distribution in Obese Women
Obesity · Metabolic Syndrome
Primary: In Vivo Adipose Cell Formation (Adipogenesis) — -0.3; 1.8; -1.2; 2.1 percent
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=81 Effects of Different Surgical Methods to Treat Obesity
Obesity · Type 2 Diabetes · Insulin Sensitivity
Primary: Insulin Sensitivity at 2 Years — 6.7; 6.6 glucose/kg body weight/min
Phase 2 N=60 Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese
Abdominal Obesity · Growth Hormone Deficiency
Primary: Change in Visceral Adipose Tissue Volume — -16; 19 cm2
N/A N=57 Insulin-sensitive Obesity: Lessons From Longitudinal Data
Insulin Sensitivity/Resistance · Obesity
Primary: Insulin Sensitivity — 0.0105; -0.0076; 0.0041 micro mol/min/Kg/mU/L/year
Phase 2 N=22 Effect of Recombinant Human Growth Hormone (rhGH) on Abdominal Fat and Cardiovascular Risk in Obese Girls
Obesity
Primary: Change in Visceral and Subcutaneous Abdominal Adipose Tissue Over 6 Months — 57; 799; -111; 3634 mm^2 — p=0.70
N/A N=47 Antecedents of Obesity: Fetal Measures of Adiposity
Obesity
Primary: Infant Adiposity at 24-72 Hours Following Birth — 11 Percentage of total body weight
N/A N=18 The Effects of Chiropractic in a Population With High Central Adiposity
Abdominal Obesity
Primary: Proportion of Potential Participants Who Are Eligible. — 0.95 Proportion
N/A N=12 The Effects of Alcohol Consumption on Central Adiposity
Alcohol Drinking · Weight Loss · Adiposity
Primary: Change in Central (Abdominal) Adiposity — -0.250; -0.071 kg — p=<0.231
N/A N=142 Growth Hormone, Cardiovascular Risk, and Visceral Adiposity
Obesity
Primary: HsCRP — -1.1; 0.5; -1.3; -0.3 mg/L
N/A N=12 Soy as an Innovative Dietary Component in Abdominal Obesity Management Amongst Peri- and Early Menopausal Women
Central Obesity
Primary: Body Fat (kg) — 40.96; 40.12; 2.94; 4.26 kg
N/A N=90 Effects of CPAP on Visceral Fat Thickness
Obstructive Sleep Apnea
Primary: Mesenteric Fat Thickness — 0.96; 0.94 cm
Phase 3 N=79 Prevention of Obesity in Women Via Estradiol Regulation
Obesity
Primary: Resting Energy Expenditure (REE) — -37.8; -87.2; 14.6; -19.3 kcal/d — p=<0.05
Phase 3 N=59 Rosuvastatin in Visceral Adiposity
Abdominal Obesity
Primary: Change in Visceral Adipose Tissue Area Measured by Computed Tomography. — -1.5; 2.8 cm2
N/A N=20 Changes in Ectopic Fat Following Surgically Induced Weight Loss
Obesity · Type 2 Diabetes
Primary: Pancreatic and Liver Triglyceride (Fat) Content — 6.44; 2.08 percent
Phase 2 N=125 PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction
Healthy · Obese
Primary: Resting Energy Expenditure After 12 Weeks of Drug Therapy (kcal/Day) — 1267; 1268 kcal/day
Phase 1 N=22 PED NEONAT 20-000599 Fetal Body Composition
IUGR · Gestational Diabetes · Pregnancy Related
Primary: Maternal Visceral Adipose Tissue Volume — 97593; 169626; 96787 mm3
N/A N=29 Clinical Effectiveness of Body Fat Distribution Imaging in Real-World Practice: The BODY-REAL Study
Overweight and Obesity · PreDiabetes · Type 2 Diabetes
Primary: Change in BMI — 0.43; 0; 4.4; 0 kg/m2 — p=0.2
N/A N=24 Omentectomy and Metabolic Syndrome
Metabolic Syndrome · Morbid Obesity
Primary: Components of Metabolic Syndrome (Body Mass Index) — 44.9; 44.5 Kg/m2 — p=0.79
N/A N=50 Bariatric Surgery for Morbid Obesity
Obesity · Morbid Obesity
Primary: Size of Adipocytes — 73.4; 99.0; 103.0 µm
N/A N=30 Estrogen Sensitivity and Ovulatory Dysfunction in Obesity
Obesity · Infertility
Primary: Luteinizing Hormone Pulse Amplitude — 2.73; 1.12 IU/L
N/A N=281 Maternal-Offspring Metabolics:Family Intervention Trial
Pregnancy · Weight Gain
Primary: Gestational Weight Gain (GWG) — 12; 10 kg — p=0.01
N/A N=60 Non-Invasive Reduction of Abdominal Fat
Fat Reduction
Primary: Proportion of Pre-treatment Images Correctly Identified — 128 photos — p=<0.001
N/A N=47 Healthy Bodies, Healthy Kids
Child Mental Disorders · Obesity · Metabolic Syndrome
Primary: DEXA-measured Adiposity — 0.76; -0.43; -2.79 kilograms — p=0.01
N/A N=27 Erythrocyte and Adipocyte G6PD Activity Levels in Obesity
Diabetes · Obesity
Primary: Measure Erythrocyte G6PD Levels in Diabetic vs. Non-diabetic Morbidly Obese Patients Undergoing Laparoscopic Gastric Bypass. — 3.12; 0.67; 22; 13 nM/min/mg — p=<0.05
N/A N=39 Sonographic Evaluation of Visceral Fat After Bariatric Surgery
Morbid Obesity
Primary: Decrease in the Visceral Fat Layer Measured by Ultrasound a Day Before and a Year After Surgery. — 3.6; 7.1; 5.6 visceral fat reduction in centimeters
Phase 3 N=793 Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)
Central Abdominal Bulging
Primary: Percentage of Subjects Who Achieved a Composite P-GAPS1/CPnS2 Response — 37; 48 Participants — p=0.397
N/A N=60 Dysregulation of FSH in Obesity: Functional and Statistical Analysis
Obesity · Fertility
Primary: Difference Between Peak Inhibin B — 100.8; 38.8 picograms/mL
N/A N=20 Cognition and Magnetic Resonance Imaging of Brain Inflammation in Obesity
Obesity
Primary: Brain Inflammation Metrics in Obese and Normal-weight Individuals as Measured by Magnetic Resonance Image-based Diffusion Basis Spectrum Imaging (DBSI) — .0468; .0492…
N/A N=271 Weight Discrimination and Poor Cardiovascular Health
Obesity
Primary: Negative Affect — 1.43; 1.29 score on a scale — p=.007
N/A N=9 Toward an Automated Method of Abdominal Fat Segmentation of MR Images
Obesity
Primary: Visceral Fat Volume With Automated Analysis — 994 cubic centimeters